{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:03:18Z","timestamp":1792713798172,"version":"4.5.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["1S76421N"],"award-info":[{"award-number":["1S76421N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["1S69721N"],"award-info":[{"award-number":["1S69721N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-026-04343-w","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T11:46:28Z","timestamp":1773143188000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Protein-level profiling of TIGIT axis components in human PDAC reveals immune\u2013suppressive expression patterns"],"prefix":"10.1007","volume":"75","author":[{"given":"D.","family":"Quatannens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Verhoeven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"van der Heijden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Peeters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Claes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Hermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Lambrechts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Zwaenepoel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"van Dam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Peeters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Prenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Koljenovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"De Waele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Faes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Lardon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Roeyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Smits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Van Audenaerde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"key":"4343_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A (2024) Cancer statistics, 2024. CA Cancer J Clin 74:12\u201349","journal-title":"CA Cancer J Clin"},{"key":"4343_CR2","doi-asserted-by":"publisher","first-page":"6527","DOI":"10.3748\/wjg.v27.i39.6527","volume":"27","author":"A Jain","year":"2021","unstructured":"Jain A, Bhardwaj V (2021) Therapeutic resistance in pancreatic ductal adenocarcinoma: current challenges and future opportunities. World J Gastroenterol 27:6527","journal-title":"World J Gastroenterol"},{"key":"4343_CR3","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1056\/NEJMoa032295","volume":"350","author":"JP Neoptolemos","year":"2004","unstructured":"Neoptolemos JP et al (2004) A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350:1200\u20131210","journal-title":"N Engl J Med"},{"key":"4343_CR4","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1001\/jama.2013.279201","volume":"310","author":"H Oettle","year":"2013","unstructured":"Oettle H et al (2013) Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA 310:1473\u20131481","journal-title":"JAMA"},{"issue":"10","key":"4343_CR5","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1001\/jama.2010.1275","volume":"304","author":"JP Neoptolemos","year":"2010","unstructured":"Neoptolemos JP et al (2010) Adjuvant chemotherapy with fluorouracil plus folinic acid versus gemcitabine following pancreatic cancer resection a randomized controlled trial. JAMA 304(10):1073\u20131081","journal-title":"JAMA"},{"key":"4343_CR6","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1001\/jamaoncol.2022.3829","volume":"8","author":"T Conroy","year":"2022","unstructured":"Conroy T et al (2022) Five-year outcomes of FOLFIRINOX versus gemcitabine as adjuvant therapy for pancreatic cancer: a randomized clinical trial. JAMA Oncol 8:1571\u20131578","journal-title":"JAMA Oncol"},{"key":"4343_CR7","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1200\/JCO.2016.67.1412","volume":"34","author":"DPS Sohal","year":"2016","unstructured":"Sohal DPS et al (2016) Metastatic pancreatic cancer: American society of clinical oncology clinical practice guideline. J Clin Oncol 34:2784\u20132796","journal-title":"J Clin Oncol"},{"key":"4343_CR8","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.3390\/curroncol29050247","volume":"29","author":"Y Shiravand","year":"2022","unstructured":"Shiravand Y et al (2022) Immune checkpoint inhibitors in cancer therapy. Curr Oncol 29:3044","journal-title":"Curr Oncol"},{"key":"4343_CR9","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer JR et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455","journal-title":"N Engl J Med"},{"key":"4343_CR10","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1097\/CJI.0b013e3181eec14c","volume":"33","author":"RE Royal","year":"2010","unstructured":"Royal RE et al (2010) Phase 2 trial of single agent ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother 33:828","journal-title":"J Immunother"},{"key":"4343_CR11","doi-asserted-by":"publisher","first-page":"4286","DOI":"10.1158\/1078-0432.CCR-14-2607","volume":"21","author":"A Patnaik","year":"2015","unstructured":"Patnaik A et al (2015) Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. Clin Cancer Res 21:4286\u20134293","journal-title":"Clin Cancer Res"},{"key":"4343_CR12","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1001\/jamaoncol.2019.1588","volume":"5","author":"EM O\u2019Reilly","year":"2019","unstructured":"O\u2019Reilly EM et al (2019) Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial. JAMA Oncol 5:1431","journal-title":"JAMA Oncol"},{"key":"4343_CR13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ebiom.2019.02.008","volume":"40","author":"G Capurso","year":"2019","unstructured":"Capurso G, Sette C (2019) Drug resistance in pancreatic cancer: new player caught in act. EBioMedicine 40:39\u201340","journal-title":"EBioMedicine"},{"key":"4343_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.1020888","volume":"9","author":"SK Hsu","year":"2022","unstructured":"Hsu SK et al (2022) Culprits of PDAC resistance to gemcitabine and immune checkpoint inhibitor: tumour microenvironment components. Front Mol Biosci 9:1020888","journal-title":"Front Mol Biosci"},{"key":"4343_CR15","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1038\/s43018-020-00121-4","volume":"1","author":"NG Steele","year":"2020","unstructured":"Steele NG et al (2020) Multimodal mapping of the tumor and peripheral blood immune landscape in human pancreatic cancer. Nat Cancer 1:1097","journal-title":"Nat Cancer"},{"key":"4343_CR16","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.ccell.2021.07.007","volume":"39","author":"WA Freed-Pastor","year":"2021","unstructured":"Freed-Pastor WA et al (2021) The CD155\/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer. Cancer Cell 39:1342-1360.e14","journal-title":"Cancer Cell"},{"issue":"1","key":"4343_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-024-55424-2","volume":"16","author":"S Sivakumar","year":"2025","unstructured":"Sivakumar S et al (2025) (2025) Distinct immune cell infiltration patterns in pancreatic ductal adenocarcinoma (PDAC) exhibit divergent immune cell selection and immunosuppressive mechanisms. Nat Commun 16(1):1\u201320","journal-title":"Nat Commun"},{"key":"4343_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13407","author":"H Harjunp\u00e4\u00e4","year":"2019","unstructured":"Harjunp\u00e4\u00e4 H, Guillerey C (2019) TIGIT as an emerging immune checkpoint. Clinical Exp Immunol. https:\/\/doi.org\/10.1111\/cei.13407","journal-title":"Clinical Exp Immunol"},{"key":"4343_CR19","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1093\/intimm\/dxab085","volume":"33","author":"A Shibuya","year":"2021","unstructured":"Shibuya A, Shibuya K (2021) DNAM-1 versus TIGIT: competitive roles in tumor immunity and inflammatory responses. Int Immunol 33:687\u2013692","journal-title":"Int Immunol"},{"key":"4343_CR20","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.immuni.2022.02.005","volume":"55","author":"KL Banta","year":"2022","unstructured":"Banta KL et al (2022) Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses. Immunity 55:512","journal-title":"Immunity"},{"key":"4343_CR21","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1470-2045(22)00226-1","volume":"23","author":"BC Cho","year":"2022","unstructured":"Cho BC et al (2022) Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. Lancet Oncol 23:781\u2013792","journal-title":"Lancet Oncol"},{"key":"4343_CR22","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.ccell.2014.10.018","volume":"26","author":"RJ Johnston","year":"2014","unstructured":"Johnston RJ et al (2014) The Immunoreceptor TIGIT regulates antitumor and antiviral CD8+ T cell effector function. Cancer Cell 26:923\u2013937","journal-title":"Cancer Cell"},{"key":"4343_CR23","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s00280-023-04627-3","volume":"94","author":"N Yamamoto","year":"2024","unstructured":"Yamamoto N et al (2024) Phase I study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in Japanese patients with advanced or metastatic solid tumors. Cancer Chemother Pharmacol 94:109\u2013115","journal-title":"Cancer Chemother Pharmacol"},{"key":"4343_CR24","doi-asserted-by":"publisher","first-page":"W556","DOI":"10.1093\/nar\/gkz430","volume":"47","author":"Z Tang","year":"2019","unstructured":"Tang Z, Kang B, Li C, Chen T, Zhang Z (2019) GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res 47:W556","journal-title":"Nucleic Acids Res"},{"key":"4343_CR25","volume-title":"TNM classification of malignant tumours - Google Books","author":"JD Brierley","year":"2017","unstructured":"Brierley JD, Gospodarowicz MK, Wittekind C (2017) TNM classification of malignant tumours - Google Books. Wiley, London"},{"key":"4343_CR26","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.immuni.2014.02.012","volume":"40","author":"N Joller","year":"2014","unstructured":"Joller N et al (2014) Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses. Immunity 40:569\u2013581","journal-title":"Immunity"},{"issue":"1","key":"4343_CR27","first-page":"1","volume":"8","author":"Y Ju","year":"2024","unstructured":"Ju Y et al (2024) Barriers and opportunities in pancreatic cancer immunotherapy. NPJ Precis Oncol 8(1):1\u201318","journal-title":"NPJ Precis Oncol"},{"key":"4343_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01878","volume":"9","author":"D Kabacaoglu","year":"2018","unstructured":"Kabacaoglu D, Ciecielski KJ, Ruess DA, Alg\u00fcl H (2018) Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: current limitations and future options. Front Immunol 9:396649","journal-title":"Front Immunol"},{"key":"4343_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004711","author":"EY Chiang","year":"2022","unstructured":"Chiang EY, Mellman I (2022) TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2022-004711","journal-title":"J Immunother Cancer"},{"key":"4343_CR30","doi-asserted-by":"publisher","first-page":"27","DOI":"10.21037\/cco-23-8","volume":"12","author":"SZH Liew","year":"2023","unstructured":"Liew SZH et al (2023) Geographical, ethnic, and genetic differences in pancreatic cancer predisposition. Chin Clin Oncol 12:27\u201327","journal-title":"Chin Clin Oncol"},{"key":"4343_CR31","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/jama.2021.13027","volume":"326","author":"W Park","year":"2021","unstructured":"Park W, Chawla A, O\u2019Reilly EM (2021) Pancreatic cancer: a review. JAMA 326:851","journal-title":"JAMA"},{"issue":"11","key":"4343_CR32","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1007\/s12264-023-01082-1","volume":"39","author":"B Ni","year":"2023","unstructured":"Ni B et al (2023) (2023) Crosstalk between peripheral innervation and pancreatic ductal adenocarcinoma. Neurosci Bull 39(11):1717\u20131731","journal-title":"Neurosci Bull"},{"issue":"1","key":"4343_CR33","doi-asserted-by":"publisher","first-page":"zard125","DOI":"10.1093\/bjsopen\/zrad125","volume":"8","author":"R Goess","year":"2024","unstructured":"Goess R et al (2024) Lymph node examination and survival in resected pancreatic ductal adenocarcinoma: retrospective study. BJS Open 8(1):zard125","journal-title":"BJS Open"},{"issue":"1","key":"4343_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms15095","volume":"8","author":"JL Carstens","year":"2017","unstructured":"Carstens JL et al (2017) (2017) Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer. Nat Commun 8(1):1\u201313","journal-title":"Nat Commun"},{"key":"4343_CR35","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1073\/pnas.1811067116","volume":"116","author":"J Blando","year":"2019","unstructured":"Blando J et al (2019) Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Proc Natl Acad Sci USA 116:1692\u20131697","journal-title":"Proc Natl Acad Sci USA"},{"key":"4343_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0091551","volume":"9","author":"Y Tang","year":"2014","unstructured":"Tang Y et al (2014) An increased abundance of tumor-infiltrating regulatory T cells is correlated with the progression and prognosis of pancreatic ductal adenocarcinoma. PLoS ONE 9:e91551","journal-title":"PLoS ONE"},{"issue":"1","key":"4343_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-017-00608-2","volume":"8","author":"N Jacquelot","year":"2017","unstructured":"Jacquelot N et al (2017) Predictors of responses to immune checkpoint blockade in advanced melanoma. Nat Commun 8(1):1\u201313","journal-title":"Nat Commun"},{"key":"4343_CR38","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1038\/s41590-020-0769-3","volume":"21","author":"S Kumagai","year":"2020","unstructured":"Kumagai S et al (2020) The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies. Nat Immunol 21:1346\u20131358","journal-title":"Nat Immunol"},{"key":"4343_CR39","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.162978","author":"X Ma","year":"2023","unstructured":"Ma X et al (2023) Human HLA-DR+CD27+ regulatory T cells show enhanced antigen-specific suppressive function. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.162978","journal-title":"JCI Insight"},{"key":"4343_CR40","doi-asserted-by":"publisher","first-page":"4622","DOI":"10.4049\/jimmunol.176.8.4622","volume":"176","author":"C Baecher-Allan","year":"2006","unstructured":"Baecher-Allan C, Wolf E, Hafler DA (2006) MHC class II expression identifies functionally distinct human regulatory T cells. J Immunol 176:4622\u20134631","journal-title":"J Immunol"},{"key":"4343_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00496","volume":"10","author":"SA Lim","year":"2019","unstructured":"Lim SA et al (2019) Defective localization with impaired tumor cytotoxicity contributes to the immune escape of NK cells in pancreatic cancer patients. Front Immunol 10:496","journal-title":"Front Immunol"},{"key":"4343_CR42","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1002\/jso.27581","volume":"129","author":"J Persky","year":"2024","unstructured":"Persky J et al (2024) Characterization of natural killer and cytotoxic T-cell immune infiltrates in pancreatic ductal adenocarcinoma. J Surg Oncol 129:885\u2013892","journal-title":"J Surg Oncol"},{"key":"4343_CR43","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1182\/bloodadvances.2018030676","volume":"3","author":"KA Stannard","year":"2019","unstructured":"Stannard KA et al (2019) Human peripheral blood DNAM-1neg NK cells are a terminally differentiated subset with limited effector functions. Blood Adv 3:1681","journal-title":"Blood Adv"},{"key":"4343_CR44","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1084\/jem.20032206","volume":"199","author":"N Reymond","year":"2004","unstructured":"Reymond N et al (2004) DNAM-1 and PVR regulate monocyte migration through endothelial junctions. J Exp Med 199:1331","journal-title":"J Exp Med"},{"key":"4343_CR45","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1084\/jem.20030788","volume":"198","author":"C Bottino","year":"2003","unstructured":"Bottino C et al (2003) Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med 198:557","journal-title":"J Exp Med"},{"key":"4343_CR46","doi-asserted-by":"publisher","first-page":"902","DOI":"10.4049\/jimmunol.0903225","volume":"184","author":"CJ Chan","year":"2010","unstructured":"Chan CJ et al (2010) DNAM-1\/CD155 interactions promote cytokine and NK cell-mediated suppression of poorly immunogenic melanoma metastases. J Immunol 184:902\u2013911","journal-title":"J Immunol"},{"key":"4343_CR47","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/icb.2011.15","volume":"90","author":"B Sanchez-Correa","year":"2012","unstructured":"Sanchez-Correa B et al (2012) Decreased expression of DNAM-1 on NK cells from acute myeloid leukemia patients. Immunol Cell Biol 90:109\u2013115","journal-title":"Immunol Cell Biol"},{"key":"4343_CR48","doi-asserted-by":"publisher","DOI":"10.1093\/JIMMUN\/VKAF293","author":"PM Saunders","year":"2025","unstructured":"Saunders PM et al (2025) CD155 density on target cells drives divergent natural killer cell responses owing to DNAM-1 loss. J Immunol. https:\/\/doi.org\/10.1093\/JIMMUN\/VKAF293","journal-title":"J Immunol"},{"key":"4343_CR49","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.121157","author":"J Fourcade","year":"2018","unstructured":"Fourcade J et al (2018) CD226 opposes TIGIT to disrupt tregs in melanoma. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.121157","journal-title":"JCI Insight"},{"key":"4343_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.873560","volume":"13","author":"ME Brown","year":"2022","unstructured":"Brown ME et al (2022) Human CD4+CD25+CD226-tregs demonstrate increased purity, lineage stability, and suppressive capacity versus CD4+CD25+CD127lo\/-tregs for adoptive cell therapy. Front Immunol 13:873560","journal-title":"Front Immunol"},{"key":"4343_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113306","volume":"42","author":"J Ma","year":"2023","unstructured":"Ma J et al (2023) CD226 maintains regulatory T\u00a0cell phenotype stability and metabolism by the mTOR\/Myc pathway under inflammatory conditions. Cell Rep 42:113306","journal-title":"Cell Rep"},{"key":"4343_CR52","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000957","author":"JM Chauvin","year":"2020","unstructured":"Chauvin JM, Zarour HM (2020) TIGIT in cancer immunotherapy. J ImmunoTher Cancer. https:\/\/doi.org\/10.1136\/jitc-2020-000957","journal-title":"J ImmunoTher Cancer"},{"key":"4343_CR53","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1158\/1078-0432.CCR-23-0258","volume":"29","author":"M Heiduk","year":"2023","unstructured":"Heiduk M et al (2023) TIGIT expression delineates T-cell populations with distinct functional and prognostic impact in pancreatic cancer. Clin Cancer Res 29:2638\u20132650","journal-title":"Clin Cancer Res"},{"key":"4343_CR54","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/379568","volume":"2015","author":"S Liang","year":"2015","unstructured":"Liang S et al (2015) The clinical and pathological significance of Nectin-2 and DDX3 expression in pancreatic ductal adenocarcinomas. Dis Markers 2015:379568","journal-title":"Dis Markers"},{"key":"4343_CR55","first-page":"2287","volume":"35","author":"S Nishiwada","year":"2015","unstructured":"Nishiwada S et al (2015) Clinical significance of CD155 expression in human pancreatic cancer. Anticancer Res 35:2287\u20132297","journal-title":"Anticancer Res"},{"key":"4343_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216985","volume":"595","author":"DJ Agorku","year":"2024","unstructured":"Agorku DJ, Bosio A, Alves F, Str\u00f6bel P, Hardt O (2024) Colorectal cancer-associated fibroblasts inhibit effector T cells via NECTIN2 signaling. Cancer Lett 595:216985","journal-title":"Cancer Lett"},{"key":"4343_CR57","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1111\/1759-7714.14981","volume":"14","author":"Y Yin","year":"2023","unstructured":"Yin Y et al (2023) High density and proximity of CD8+ T cells to tumor cells are correlated with better response to nivolumab treatment in metastatic pleural mesothelioma. Thorac Cancer 14:1991\u20132000","journal-title":"Thorac Cancer"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04343-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04343-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04343-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T13:03:30Z","timestamp":1773147810000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-026-04343-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":57,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["4343"],"URL":"https:\/\/doi.org\/10.1007\/s00262-026-04343-w","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"assertion":[{"value":"14 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent was obtained from all individual participants included in the study.Ethical approvalThis study was approved by the Ethics Committee of the University of Antwerp (Antwerp, Belgium) and the Antwerp University Hospital (Antwerp, Belgium) under the reference number 14\/47\/480.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"99"}}